CureVac N.V. CVAC 深 沪
已收盘 12-19 16:00:00 美东时间
4.165
-0.115
-2.69%
华盛通- 最 高5.55
- 今 开4.15
- 成交量 260.99万股
- 最 低 4.07
- 昨 收 4.28
- 总市值 7.79亿
- 52周最高 5.72
- 市盈率 静 --
- 换手率 1.40%
- 52周最低 2.475
- 委 比 47.59%
- 总股本 1.87亿
- 历史最高 151.80
- 量 比 2.00
- 振 幅 34.58%
- 历史最低 1.10
- 每 手 1
- 风险率 1.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more ...
11-24 22:47
CureVac Q3 EPS $1.41 Beats $(0.17) Estimate, Sales $63.295M Beat $14.520M Estimate
CureVac (NASDAQ:CVAC) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $(0.17) by 929.41 percent. This is a 687.5 percent increase over losses of $(0.24) per share from the same
11-24 21:18
CureVac(CVAC)涨近4成 获BioNTech12.5亿美元全股票收购
金吾财讯 | CureVac(CVAC)股价走高，截止发稿，涨39.43%，报5.675美元。 消息面上，公司同意以全股票形式被新冠疫苗生产商、德国同行BioNTech(BNTX)收购，交易价值约12.5亿美元。公司表示，其投资者持有的每股CureVac股票将获得价值约5.46美元的BioNTech美国存托股票。这比昨日收盘价溢价34%。
06-12 23:31
德国生物新技术公司将以全股票方式收购CureVac
美东时间周四早间，生物技术制药厂CureVac（CVAC）股价上涨38%，此前德国生物新技术公司（BioNTech，BNTX）宣布以全股票交易方式收购该公司，交易估值达12.5亿美元。 德国生物新技术公司称，此项战略举措旨在强化该公司旗下信使核糖核酸（mRNA）技术实力，与其肿瘤学战略形成协同效应。 公告发布后，CureVac股价大涨26%，反映出投资者对该并购潜在协同效应的信心。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
06-12 22:50
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
BioNTech is acquiring CureVac to enhance mRNA-based cancer immunotherapy. The all-stock deal, with a 55% premium, leverages complementary capabilities and aims to create long-term value, expected to close in 2025.
06-12 10:45
JMP Securities Reiterates Market Outperform on CureVac, Maintains $16 Price Target
JMP Securities analyst Roy Buchanan reiterates CureVac (NASDAQ:CVAC) with a Market Outperform and maintains $16 price target.
2024-09-16 22:04
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.
2024-09-12 23:32
JMP Securities Maintains Market Outperform on CureVac, Lowers Price Target to $16
JMP Securities analyst Roy Buchanan maintains CureVac (NASDAQ:CVAC) with a Market Outperform and lowers the price target from $18 to $16.
2024-08-16 20:02
CureVac's Q2 Pre-Tax Loss Widens, Revenue Rises; Finance Chief Pierre Kemula to Depart
08:24 AM EDT, 08/15/2024 (MT Newswires) -- CureVac (CVAC) reported a Q2 pre-tax loss Thursday of 71.2 million euros ($78.4 million), widening from a loss of 67.4 million euros a year earlier. Revenue for the quarter ended June 30 was 14.4 million euros, up from 7.6 million euros a year earlier. Anal...
2024-08-15 20:24
